Transgene Sa Stock Fundamentals
| TRGNF Stock | USD 1.59 0.00 0.00% |
Transgene SA fundamentals help investors to digest information that contributes to Transgene's financial success or failures. It also enables traders to predict the movement of Transgene Pink Sheet. The fundamental analysis module provides a way to measure Transgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transgene pink sheet.
Transgene |
Transgene SA Company Return On Equity Analysis
Transgene's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Transgene Return On Equity | -0.36 |
Most of Transgene's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Transgene SA has a Return On Equity of -0.3623. This is 98.49% lower than that of the Healthcare sector and 99.01% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 16.87% higher than that of the company.
Transgene SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Transgene's current stock value. Our valuation model uses many indicators to compare Transgene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Transgene competition to find correlations between indicators driving Transgene's intrinsic value. More Info.Transgene SA is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Transgene's earnings, one of the primary drivers of an investment's value.Transgene Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transgene's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics of similar companies.Transgene is currently under evaluation in return on equity category among its peers.
Transgene Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X | |||
| Revenue | 9.99 M | |||
| Gross Profit | (15.87 M) | |||
| EBITDA | (16.55 M) | |||
| Net Income | (19.54 M) | |||
| Cash And Equivalents | 49.57 M | |||
| Cash Per Share | 0.50 X | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 4.27 X | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Number Of Employees | 143 | |||
| Beta | 0.79 | |||
| Market Capitalization | 212.74 M | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (500 M) | |||
| Working Capital | 27 M | |||
| Current Asset | 51 M | |||
| Current Liabilities | 24 M | |||
| Z Score | -5.6 | |||
| Net Asset | 101.84 M |
About Transgene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transgene SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.